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Introduction
Multiple sclerosis (MS) is a chronic autoimmune 
disease affecting the central nervous system 
(CNS). It typically begins in young adulthood, 
mostly with a relapsing disease course.1 Relapses 
represent focal autoimmune inflammatory CNS 
lesions that cause the acute occurrence of new 
neurological symptoms or the worsening of pre-
existing deficits lasting for longer than 24 h.2 The 
most established treatment option for MS relapse 
is a pulse therapy with systemic glucocorticoids 
(GC) due to their pleiotropic immunological 
effects.3–5 Although in our hospital, we stick to 
the guidelines of the German Neurology Society 
(Deutsche Gesellschaft für Neurologie, DGN6) 
for the GC administration, we need to adapt this 
scheme from case-to-case. This is particularly 
important because GC doses needed to achieve 
sufficient symptom control differ between each 
patient. The DGN suggests a 3–5 day course of 
intravenous methylprednisolone (or equivalent) 
1000 mg/day.6 This course may be repeated if 
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Abstract
Background: Glucocorticoid (GC) pulse therapy is used for multiple sclerosis (MS) relapse 
treatment; however, GC resistance is a common problem. Considering that GC dosing is 
individual with several response-influencing factors, establishing a predictive model, which 
supports clinicians to estimate the maximum GC dose above which no additional therapeutic 
value can be expected presents a huge clinical need.
Method: We established two, independent retrospective cohorts of MS patients. The first 
was an explorative cohort for model generation, while the second was established for its 
validation. Using the explorative cohort, a multivariate regression analysis with the GC dose 
used as the dependent variable and serum vitamin D (25D) concentration, sex, age, EDSS, 
contrast enhancement on cranial magnetic resonance imaging (MRI), immune therapy, and 
the involvement of the optic nerve as independent variables was established.
Results: In the explorative cohort, 113 MS patients were included. 25-hydroxyvitamin D (25D) 
serum concentration and the presence of optic neuritis were independent predictors of the 
GC dose needed to treat MS relapses [(25D): −25.95 (95% confidence interval (CI)): −47.40 
to −4.49; p = 0.018; optic neuritis: 2040.51 (95% CI: 584.64–3496.36), p = 0.006]. Validation of 
the multivariate linear regression model was performed within a second cohort. Here, the 
predicted GC dose did not differ significantly from the dose administered in clinical routine 
(mean difference: −843.54; 95% CI: −2078.08–391.00; n = 30, p = 0.173).
Conclusion: Our model could predict the GC dose given in clinical, routine MS relapse care, 
above which clinicians estimate no further benefit. Further studies should validate and 
improve our algorithm to help the implementation of predictive models in GC dosing.
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symptom control is insufficient. Nevertheless, in 
patients who do not respond to high dosages of 
GC, plasma exchange may be needed for relapse 
treatment.3
The biomolecular understanding of the mecha-
nisms underlying GC resistance has already been 
deepened. For example, the significance of an 
altered level of glucocorticoid receptor (GR) 
complex7 is appreciated as an important factor. In 
addition, the role of vitamin D (VD) in dexa-
methasone-induced binding of the GR to GC 
response elements,8 and the inhibition of the 
mechanistic target of rapamycin (mTOR) path-
way, which generally regulates cell metabolism, 
growth, proliferation, survival, and which appears 
to also be relevant for GC signaling, as it upregu-
lates the GR as shown by our group in human and 
murine T cells. This leads to increased 
GC-induced effects, which have previously been 
described.9,10 However, no predictive clinical 
model exists that can be used to determine the 
individual dose of GC needed for relapse treat-
ment until either sufficient symptom control is 
achieved, or a further escalation of the GC dose is 
not appropriate due to GC resistance. Therefore, 
the aim of this study is to establish such a predic-
tive model, based only on the clinical data avail-
able at the time point of relapse, in order to 




We conducted a retrospective bicentric study and 
established two independent cohorts. The first 
was an explorative cohort, while the second was a 
validation cohort. For description of patient iden-
tification and cohort definition, please refer to 
Figure 1.
Evaluated data
The following eight variables were extracted from 
medical records: (I) The serum level of 25D: only 
values dating no more than 3 months prior or 
after the relapse were included. (II) Sex. (III) Age 
at the time of relapse. (IV) Expanded Disability 
Status Scale (EDSS) score at the time of relapse. 
If no clear EDSS number was written in medical 
reports, we recalculated it only if every needed 
clinical data was described accurately at the time 
of relapse. If some information (for example vis-
ual acuity or information on bowel and bladder 
function) was missing, the EDSS value of this 
patient was determined as missing. (V) The pres-
ence of any gadolinium-enhancing lesion on post 
gadolinium T1 magnetic resonance imaging 
(MRI). We analyzed cerebral and/or spinal MRIs 
to look for gadolinium uptake and considered 
contrast enhancement positive, if, on either scan, 
one or more lesions were found to uptake gado-
linium. (VI) MS treatment: treatment running at 
the time of relapse was considered. A patient was 
considered untreated whenever the last treatment 
was stopped for a longer time than the wash-out 
period for each specific medication.11 The differ-
ent immunotherapies were divided into the fol-
lowing: no treatment, first-line therapies 
(interferons, glatiramer acetate, dimethyl fuma-
rate, teriflunomide), and second-line therapies 
(fingolimod, natalizumab, rituximab) according 
to the European Medicines Agency. (VII) The 
presence of an optic neuritis. Optic neuritis was 
considered present if clinical reports mentioned 
according symptoms. The main parameter 
assessed to evaluate optic neuritis was visual acu-
ity. (VIII) The dose of glucocorticoids used. We 
summed up the total amount of GC administered 
in milligrams. The main GC used was methyl-
prednisolone. If dexamethasone was adminis-
tered, we added the amount as methyl-prednisolone 
equivalent dose by multiplying the dexametha-
sone in milligrams by 4.
Study endpoints
The study endpoint was to develop a regression 
model to predict the GC dose used for relapse 
treatment. Treatment stop with GC could have 
two reasons: recovery of relapse symptoms 
[defined as sufficient symptom control without 
any left symptoms affecting the daily life (n = 60 
patients with a decrease of EDSS and 10 with a 
stable EDSS)] or poor steroid response [defined 
as therapy escalation to plasmapheresis (n = 43 
received PLEX (two, despite a decreased EDSS 
due to a devastating disability of the relapse, and 
eight with an increased EDSS after steroids and 
33 with no EDSS change)].
Statistics
We used IBM SPSS statistics 25 (Armonk, 
USA) to analyze the data. Comparative statistics 
were used to compare categorical and 
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continuous variables between both data sets. 
For the prediction of GC dose, a multivariate 
regression analysis with GC dose used as the 
dependent variable and 25D level, sex, age, 
EDSS, contrast enhancement, immune ther-
apy, and the involvement of optic nerve as 
independent variables was performed. 
Afterwards, this model was used to calculate 
the GC dose of the validation cohort. To do so, 
we retrieved the clinical data of all above-men-
tioned independent variables in our validation 
cohort. By inserting those in the formula of the 
(a)
(b)
Figure 1. Flowchart of the cohort formation process. We screened outpatient wards. (a) For the explorative 
cohort in Bochum from March 2013 until August 2015 (employment period of co-author at the Hospital of 
Bochum) and in Bern from 2014 (beginning of specialized neuroimmunological consultation) until March 2019. 
(b) For the validation cohort in Bern from March 2019 until December 2019. Screening terms were as listed 
above. We included any type of MS except progressive forms. Only 1 secondary progressive MS patient was 
included in Bern, because he had a clear relapse including MRI-enhancing lesions. By adding GC application, 
we restricted all found MS patients to those with acute relapse symptoms. If any needed value (GC dose, MRI, 
EDSS, 25D) could not be retrieved, patients were excluded from the analysis.
25D, 25-hydroxy-vitamin D; CIS, clinically isolated syndrome; EDSS, expanded disability status scale; GC, glucocorticoids; 
MS, multiple sclerosis; PLEX, plasma exchange; Tx, therapy.
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regression analysis retrieved within the explora-
tive cohort, we were able to calculate the sup-
posedly ‘optimal’ GC dosage for each patient. 
This dose was then subtracted from the GC 
each patient received in the real setting, in order 
to assess whether our model could predict GC 
dose in a separate and independent cohort.
Ethics statement
This study was performed under the ethics votes 
KEK-BE 2017-01369 for Bern, Switzerland 
and 4801-13 for Ruhr-University Bochum, 
Germany, and followed the principles of the 
Declaration of Helsinki.
Results
The basic characteristics of the explorative and 
the validation cohorts are presented in Table 1. 
Most variables were equally-distributed between 
the cohorts, except for EDSS and 25D serum 
concentrations; these were both higher in the 
explorative cohort compared with the validation 
cohort (Table 1).
Receiver operating characteristic (ROC) curve 
analysis revealed that the highest sensitivity and 
specificity, to distinguish between patients experi-
encing sufficient symptom control through ster-
oid treatment versus those needing escalation 
treatment, was at a GC dose of 6100 mg, with a 
specificity of 60.5% and a sensitivity of 75.5% 
(data not shown).
With the regression analysis performed as 
described under methods, we found that 25D 
serum concentration and the presence of optic 
neuritis were independent predictors of the GC 
dose needed to treat the present MS relapse 
[regression coefficient of 25D serum concentra-
tion: −25.95 (95% CI: −47.40 to −4.49), 
p = 0.018; regression coefficient of optic neuritis: 
2040.5 (95% CI: 584.64–3496.36), p = 0.006] 
[Figure 2(a) and (b)].
In the clinical context, this signifies that the higher 
the VD serum level of a patient, the smaller the 
volume GC needed to treat relapse. However, if 
optic neuritis was present in a relapsed patient, 
higher GC dosages were applied. Furthermore, 
the following formula was retrieved by multivari-
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In a second step, the validation cohort was used 
to proof the relevance of our statistical model by 
comparing the used GC dose with the one calcu-
lated with the above-described model. It demon-
strated that our model predicted the cumulative 
GC dose in the validation cohort (mean differ-
ence: −843.54; 95% CI: −2078.08–391.00; 
p = 0.173) (Figure 3). Practically applied, this 
would signify that by taking selected clinical 
patient aspects and inserting these into our for-
mula, we could calculate a supposedly optimal-
limit of GC individually for every patient. It is 
important to highlight that our study does not 
argue for the safe treatment option of ultra-high 
dosages of vitamin D exceeding the limit of a 
normal range, as this is known to be associated 
with possibly-severe side effects.
Conclusion
Our study aims to identify a predictive model for 
the cumulative GC dose needed for the treatment 
of MS relapses. As previously demonstrated by our 
group and others8,10, 25D serum concentration 
was negatively associated with GC dose, highlight-
ing VD as a risk factor for poor GC response. 
Furthermore, the presence of an optic neuritis was 
also independently-associated with the need for 
higher doses of GC. The available data on the 
effectiveness of intravenous or oral GC on optic 
neuritis points towards restricted benefit, with only 
a positive effect on the rate of return to normal 
visual acuity but not on the pooled risk-ratio of 
normal visual acuity, normal contrast sensitivity, 
and normal visual fields.12 This might point 
towards underlying, as yet unknown, pathomecha-
nisms in optic neuritis, making GC administration 
less effective than in other MS relapse symptoms. 
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However, the same study showed a faster recovery 
with intravenous steroids compared with oral or no 
treatment. Therefore, our findings of higher dos-
ages used for ON treatment might be the result of 
a more aggressive treatment because of the disa-
bling visual symptom. Finally, the developed 
model could be validated using a second inde-
pendent validation cohort, as the calculated dose 
did not differ significantly from the dose given in 
clinical settings.
The limitations of our study will be detailed. When 
analyzing the administrated GC dose, we investi-
gated physicians’ decisions. Therefore, as centers 
included are both European German speaking 
centers (Bochum, Germany and Bern, Switzerland) 
an international validation should follow. For the 
regression analysis, we included clinical aspects 
that are, in our opinion, most relevant and can be 
retrieved easily at the time point of relapse. 
However, this might not comprise all relevant 
Figure 2. The glucocorticoid dose of every patient plotted against respective vitamin D serum level. (a) In the 
explorative cohort. (b) In the validation cohort. Vitamin D was found to be an independent predictor for the GC 
dose administered in a linear regression analysis (regression coefficient of vitamin D: −25.95 (95% CI: −47.40 to 
−4.49), p = 0.018), Nagelkerks R2 = 0.17.
25D, 25-hydroxy-vitamin D; CI, confidence interval; EDSS, expanded disability status scale; GC, glucocorticoids; ImmuneTx, 
immunotherapy.
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clinical aspects, which could be a limitation of our 
study. Including a baseline EDSS, rather than the 
EDSS at the time point of relapse would be inter-
esting. We lacked this information for many 
patients, since, at time of inclusion, many received 
their initial diagnosis of MS while others presented 
for the first time in our department, having been 
treated at other facilities prior to the study. A fur-
ther limitation is the retrospective design of the two 
cohorts and the small patient number of the valida-
tion cohort in comparison to the explorative cohort.
Considering that GC dosing appears to be indi-
vidual with a range used in our cohort from 480 
to 19,000 mg, with several factors influencing GC 
response, including the presence of an optic neu-
ritis or VD serum concentration, establishing 
patient specific models, which support clinicians 
to estimate the GC dosage from which no more 
therapeutic added value, as suggested by our ret-
rospective data analysis, might be expected has an 
obvious clinical need. Further studies should vali-
date and further develop our algorithm to improve 
the prediction of clinically-needed GC dose.
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Figure 3. For this boxplot, we took the validation 
cohort and subtracted from each patient the 
glucocorticoid dose (in mg) administered in real life 
from the one we calculated applying the regression 
analysis established in the explorative cohort. 
The median is shown as bar of the boxplot. The 
high values are rare cases with prolonged relapse 
symptoms, where our steroid dosing regimen was 
administered repeatedly (e.g. after a 7 day course of 
steroid administration the symptoms did not improve, 
but GC had been well tolerated, we would decide to 
administer steroids for another 5–7 days). There was 
no significant difference between the dosages [one 
sample t-test (test value 0), p = 0.173; box: median, 
25–75 percentile; whisker: 10–90 percentile].
GC, glucocorticoids.
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